Document Classification

Section Type: RESULTS

Text: The beneficial clinical effects of eplerenone (as observed in the main study) were preserved for the EMPHASIS-HF primary end point in patients receiving higher doses of ACEi or angiotensin receptor blocker, - blocker, or both (hazard ratio for eplerenone versus placebo, ACEi/angiotensin receptor blocker : high dose, 0. 67 ; low dose, 0. 65 ; - blockers : high dose, 0. 55 ; low dose, 0. 72 ; both ACEi/angiotensin receptor blocker and - blocker : high dose, 0. 59 ; low dose, 0. 68 ; P value for interaction 0. 80, 0. 15, and 0. 53, respectively), as well as for all-cause mortality.